The synergistic anti‐tumor activity of curcumin and carboplatin is due to the inhibition of Akt phosphorylation that inhibits the Akt/IKKα pathway and enhancement of ERK1/2 activity to inhibit NF‐κB, allowing carboplatin to act as a chemical sensitizer.172. Here, AKT1 is linked to neoplasm.